ClinicalTrials.gg
CompletedNCT04282109NIVOTAXUpdated Jun 26, 2025Results posted

Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)

A Phase 2 interventional study of Nivolumab + Paclitaxel and Cetuximab + Paclitaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, sponsored by Grupo Español de Tratamiento de Tumores de Cabeza y Cuello. Completed at 21 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-26.

Sponsored by Grupo Español de Tratamiento de Tumores de Cabeza y Cuello · Phase 2, Interventional, and Treatment

How we know · 8 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
141
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck — 11 open to participants now, 15 under way, 2 of them phase 3. Nivolumab · Squamous Cell Carcinoma of Head and Neck.

Enrollment
9th of 46
141 · median 44
Started
2020
with 3 others
Phase 2
27 of 46
10 open now
Registered
28th of 46
by date

Among the 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck, this one is the 9th largest by enrollment, is one of 4 that started in 2020, is one of 27 in phase 2, and was the 28th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

11 of the 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck are open now, in 7 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

Chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma is palliative and usually platinum based, and the patients often present with poor physical condition. Consequently, many of them are not able to withstand a platinum-based chemotherapy. The addition of taxanes to the armamentarium of drugs improve the outcome in this group of patients. An alternative and better tolerated regimen for these patients is paclitaxel in combination with cetuximab, included the in guidelines of the Spanish Society of Medical Oncology.

Recently, new treatments such as immune-checkpoint inhibitors have shown promising activity and good tolerability in patients with recurrent or metastatic head and neck squamous cell carcinoma and has been included in the recently published guidelines from the Society for Immunotherapy of Cancer. Nivolumab (anti-PD1) has been approved for patients progressing on or after platinum-based therapy, as it clearly impacts on overall survival.

This randomized phase II study will evaluate the efficacy of nivolumab plus paclitaxel for first-line treatment of recurrent or metastatic HNSCC in the platinum ineligible and platinum refractory settings. Control arm will be paclitaxel in combination with cetuximab, treatment included in the guidelines of the Spanish Society of Medical Oncology.

03

Conditions studied

  • Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Keywords

  • Head and neck cancer
  • Squamous cell carcinoma
  • Nivolumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care.
  2. confirmed HNSCC (oral cavity, oropharynx, hypopharynx, larynx) not amenable to therapy with curative intent (surgery or radiation therapy with or without chemotherapy).
  3. Patients not previously treated for recurrent/ disease.
  4. Radiographically as defined by version 1.1. Previously irradiated lesions can only be considered as measurable disease if disease progression according to RECIST version 1.1.
  5. Patients unable for cisplatin-based chemotherapy, defined "unable" by:

    1. 70% or
    2. Karnofsky 80-100% and amenable to chemotherapy, but:

    i. Impaired renal function, >30 mL/min and \<80 mL/min could be assessed by direct measurement (EDTA or creatinine clearance) if available or by calculation from serum or plasma creatinine (see annex 5), or

    ii. grade ≥2 hearing loss, according to the v 5.0, or

    iii. Class III heart failure according to the (annex 9), or

    iv. History of allergic reactions to cisplatin, carboplatin, or other platinum-containing compounds or

    v. Prior dose of cisplatin ≥225 mg/m² for locally advanced disease (a patient who received prior RT + 3 cycles of cisplatin 100 mg/m2 or 3 cycles induction TPF (with cisplatin ≥75/m2) for locally advanced primary HN cancer can be included), or

    vi. Disease progression or relapse during or within 6 months of receiving platinum-based therapy administered as , adjuvant therapy or as concomitant chemotherapy with radiotherapy and have received at least 200 mg/m2 of cisplatin.

  6. Male or female patients aged ≥18 years. Patients aged ≥70 years old can only be included with a G8 (Geriatric 8) health status screening score ≥ 14.
  7. Clinical laboratory values as specified below within 28 days before the first dose of study drug:

    1. Total must be ≤2 × the (ULN).
    2. Magnesium ≥ lower limit of normal.
    3. Calcium ≥ lower limit of normal.
    4. and AST must be ≤3 × ULN unless liver metastases are present, in which case they must be ≤5x ULN.
    5. must be ≥9 g/dL, (ANC) must be ≥1.500/µL, WBC must be ≥2.000/µL and count must be ≥100.000/µL.
  8. Subjects who have received radiation as primary therapy are eligible if radiation therapy treatment was completed > 4 weeks prior to inclusion.
  9. Documentation of status by IHC performed by the central lab at randomization. A pre-treatment tumor tissue sample should be sent. A newly obtained (within 6 months prior to start of study treatment) is preferred but an archival sample is acceptable, if several tumor samples are available, testing should be performed on the most recently obtained tumor sample.
  10. Documentation of HPV p16 status (OPC) is required for HNSCC tumor of the oropharynx. For subjects with oropharyngeal cancer, sites are defined in annex 8. HPV status of tumor tissue has to be locally determined at screening by any of the following methods: p16 IHC, in situ hybridization, or polymerase chain reaction based assay. If HPV status by p16 IHC is positive result confirmation by PCR is mandatory.

Exclusion criteria

Exclusion Criteria:

  1. Male or female patients aged \<18 years. Patients aged ≥ 70 years old should not be included with a G8 (Geriatric 8) health status screening score \< 14.
  2. \<70%.
  3. Patients that meets more than one of the following criteria:

    1. Karnofsky 70%,
    2. Impaired renal function, >30 mL/min and \<80 mL/min could be assessed by direct measurement (EDTA or creatinine clearance) if available or by calculation from serum or plasma creatinine (see annex 5),
    3. Class III heart failure according to the (annex 9).
  4. Any unresolved toxicity Grade ≥2 from previous anticancer therapy except for alopecia, vitiligo, hear loss and the laboratory values defined in the inclusion criteria.
  5. confirmed recurrent or squamous cell carcinoma of unknown primary, of the nasopharynx or non-squamous histologies (eg, mucosal melanoma).
  6. Active or .
  7. Carcinomatous meningitis.
  8. Active, known, or suspected disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, or unexpected conditions of recurrence in the absence of an external trigger are allowed to be included.
  9. Diagnosis of immunodeficiency or any condition requiring systemic treatment with either (>10 mg daily prednisone equivalents) or other medications within 14 days of treatment.
  10. History of pneumonitis requiring treatment with steroids; history of idiopathic pulmonary fibrosis, drug-induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest CT scan; history of radiation pneumonitis in the radiation field (fibrosis) is permitted.
  11. Patients with a history of interstitial lung disease cannot be included if they have symptomatic ILD (Grade 3-4) and/or poor lung function.
  12. Prior therapy with experimental antitumor vaccines; any T-cell co-stimulation agents or inhibitors of checkpoint pathways, such as , anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody; or other agents specifically targeting T cells are prohibited.
  13. Any serious medical or psychiatric illness, including drug or alcohol abuse, that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.
  14. Life-threatening illness unrelated to cancer.
  15. Female patients who are lactating and breast-feeding or a positive serum pregnancy test during the screening period.
  16. Systemic anticancer treatment or radiotherapy less than 4 weeks or 5 half-lives, whichever is longer, before the first dose of study treatment or not recovered from acute toxic effects from prior chemotherapy and radiotherapy.
  17. Prior treatment with agents ≤21 days (≤4 weeks for monoclonal antibodies with evidence of PD) or ≤5 their half-lives (whichever is shorter) before the first dose of study treatment. A minimum of 10 days should elapse from prior therapy to initiating protocol therapy.
  18. Major surgery within 14 days before the first dose of study drug and not recovered fully from any complications from surgery.
  19. Systemic infection requiring IV antibiotic therapy or other serious infection within 14 days before the first dose of study drug.
  20. Known (HIV) positive (testing not required), or known acquired immunodeficiency syndrome (AIDS).
  21. Patients with positive test for virus or virus indicating presence of virus, eg, Hepatitis B surface antigen (HBsAg) positive, or Hepatitis C antibody (anti-HCV) positive (except if HCV-RNA negative).
  22. Active secondary that requires treatment. Patients with previous malignancies (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, endometrial, cervical/dysplasia, melanoma, or breast) are excluded unless a complete remission was achieved at least 2 years prior to study entry and no additional therapy is required during the study period
  23. Any co-morbidities, such as uncontrolled pulmonary disease, known impaired cardiac function or clinically significant cardiac disease, active central nervous system disease, active infection, or any other condition that could compromise the patient's participation in the study.
  24. Patients with history of reactions to study drugs (nivolumab, cetuximab or paclitaxel) or any of their .
  25. Symptomatic peripheral neuropathy of Grade ≥ 2 based on the CTCAE v5.0
  26. Pulmonary embolism, deep vein thrombosis, or other significant thromboembolic event ≤ 8 weeks prior to starting the study treatment.
  27. History of severe skin disorder that in the opinion of the investigator may interfere with study conduct.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
141 participants (actual)

Study arms

  • Experimental
    Arm 1

    NIVOTAX (nivolumab + paclitaxel, follow by maintenance with nivolumab)

    Drug: Nivolumab + Paclitaxel

  • Active comparator
    Arm 2

    ERBITAX (cetuximab + paclitaxel, follow by maintenance with cetuximab)

    Drug: Cetuximab + Paclitaxel

Interventions

  • DrugNivolumab + Paclitaxel

    Drug pages: NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PaclitaxelStudies of PaclitaxelPaclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Combination treatment: Nivolumab 240 mg will be administered via IV infusion every 2 weeks. Paclitaxel 80mg/m2 will be administered via IV infusion weekly. After 12 weeks from the start of the combined treatment paclitaxel will be stopped. Maintenance treatment with nivolumab 480 mg every 4 weeks will start two weeks after the last administration of nivolumab 240 mg. Once nivolumab is administered at 480 mg, paclitaxel can no longer be administered. Nivolumab will be continued alone until disease progression, unacceptable toxicity or withdrawal of consent up to a maximum of 24 months.

  • DrugCetuximab + Paclitaxel

    Drug pages: CetuximabStudies of CetuximabCetuximab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PaclitaxelStudies of PaclitaxelPaclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Combination treatment: Cetuximab 250 mg/m2 (first dose of 400 mg/m2) administered via IV infusion weekly plus weekly paclitaxel (80 mg/m2) administered via IV infusion. After 12 weeks from the start of the combined treatment paclitaxel will be stopped and weekly cetuximab will be continued alone until disease progression, unacceptable toxicity or withdrawal of consent up to a maximum of 24 months.

06

What researchers measure

Primary outcomes

  1. Two Years Overall Survival (OS)

    OS is defined as the time between the date of randomization and the date of death. For subjects without documentation of death, OS will be censored on the last date the subject was known to be alive.

    Time frame: 2 years

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as the time from randomization to the date of first documented disease progression, as assessed by the investigator using RECIST 1.1 criteria, or death due to any cause, whichever occurs first.

    Time frame: Up to 45 months

  2. Overall Response Rate (ORR)

    ORR is defined as the number of subjects with a best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized subjects for each treatment group.

    Time frame: Up to 2 years

  3. Disease Control Rate (DCR)

    Disease control rate (DCR) is defined as the number of subjects with a best overall response (BOR) of a complete response (CR), partial response (PR) or stable disease (SD) divided by the number of randomized subjects for each treatment group.

    Time frame: Up to 2 years

  4. Duration of Response (DoR)

    Duration of Response (DoR) is defined as the time between the date of first confirmed response to the date of the first documented tumor progression (per RECIST 1.1), or death due to any cause, whichever occurs first.

    Time frame: Up to 45 months

  5. 6-months Progression-free Survival Rate

    Probability of progression at 6 months.

    Time frame: 6 months

  6. Overall Survival in Patients ≥ 70 Years.

    OS is defined as the time between the date of randomization and the date of death.

    Time frame: Up to 45 months

  7. Progression Free Survival in Patients ≥ 70 Years.

    PFS is defined as the time from randomization to the date of first documented disease progression, as assessed by the investigator using RECIST 1.1 criteria, or death due to any cause, whichever occurs first.

    Time frame: Up to 45 months

  8. Overall Response Rate in Patients ≥ 70 Years.

    ORR is defined as the number of subjects with a best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized subjects for each treatment group.

    Time frame: Up to 2 years

  9. Overall Survival Based on PDL1 Expression (CPS).

    OS is defined as the time between the date of randomization and the date of death.

    Time frame: Up to 45 months

  10. Progression Free Survival Based on PDL1 Expression (CPS).

    PFS is defined as the time from randomization to the date of first documented disease progression, as assessed by the investigator using RECIST 1.1 criteria, or death due to any cause, whichever occurs first.

    Time frame: Up to 45 months

  11. Overall Response Rate Based on PDL1 Expression (CPS).

    ORR is defined as the number of subjects with a best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized subjects for each treatment group.

    Time frame: Up to 2 years

  12. Overall Survival Based on Cisplatin Ineligibility.

    OS is defined as the time between the date of randomization and the date of death.

    Time frame: Up to 45 months

  13. Progression Free Survival Based on Cisplatin Ineligibility.

    PFS is defined as the time from randomization to the date of first documented disease progression, as assessed by the investigator using RECIST 1.1 criteria, or death due to any cause, whichever occurs first.

    Time frame: Up to 45 months

  14. Overall Response Rate Based on Cisplatin Ineligibility.

    ORR is defined as the number of subjects with a best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized subjects for each treatment group.

    Time frame: Up to 2 years

  15. Overall Survival Based on Karnofsky.

    OS is defined as the time between the date of randomization and the date of death.

    Time frame: Up to 45 months

  16. Progression Free Survival Based on Karnofsky.

    PFS is defined as the time from randomization to the date of first documented disease progression, as assessed by the investigator using RECIST 1.1 criteria, or death due to any cause, whichever occurs first.

    Time frame: Up to 45 months

  17. Overall Response Rate Based on Karnofsky.

    ORR is defined as the number of subjects with a best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized subjects for each treatment group.

    Time frame: Up to 2 years

  18. Percentage of Patients With AEs

    Percentage of patients with AEs in relation with total number of treated patients

    Time frame: 2 years

  19. Percentage of Patients With Grade 3 and Grade 4 AEs

    Percentage of patients with Grade 3 and Grade 4 AEs in relation with total number of treated patients

    Time frame: 2 years

  20. Percentage of Patients With SAEs

    Percentage of patients with SAEs in relation with total number of treated patients

    Time frame: Up to 45 months

  21. Percentage of Patients Who Discontinued Due to AEs

    Percentage of patients who discontinued due to AEs in relation with total number of treated patients

    Time frame: Up to 2 years

07

Results

Posted Jun 26, 2025

Participant flow

Participant flow — Overall Study
MilestoneArm 1Arm 2
Started9348
Completed9348
Not completed00

Outcome measures

PrimaryTwo Years Overall Survival (OS)

OS is defined as the time between the date of randomization and the date of death. For subjects without documentation of death, OS will be censored on the last date the subject was known to be alive.

Time frame:
2 years
Reported as:
Number · percentage of participants
Two Years Overall Survival (OS)
percentage of participantsArm 1Arm 2
Two Years Overall Survival (OS)24.7 (15.9 to 33.5)13.4 (3.6 to 23.2)
SecondaryProgression Free Survival (PFS)

PFS is defined as the time from randomization to the date of first documented disease progression, as assessed by the investigator using RECIST 1.1 criteria, or death due to any cause, whichever occurs first.

Time frame:
Up to 45 months
Reported as:
Median · months
Progression Free Survival (PFS)
monthsArm 1Arm 2
Progression Free Survival (PFS)5.6 (3.5 to 7.6)5.3 (2.7 to 7.9)
SecondaryOverall Response Rate (ORR)

ORR is defined as the number of subjects with a best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized subjects for each treatment group.

Time frame:
Up to 2 years
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsArm 1Arm 2
Overall Response Rate (ORR)37.6 (27.8 to 47.5)37.5 (23.8 to 51.2)
SecondaryDisease Control Rate (DCR)

Disease control rate (DCR) is defined as the number of subjects with a best overall response (BOR) of a complete response (CR), partial response (PR) or stable disease (SD) divided by the number of randomized subjects for each treatment group.

Time frame:
Up to 2 years
Reported as:
Number · percentage of participants
Disease Control Rate (DCR)
percentage of participantsArm 1Arm 2
Disease Control Rate (DCR)74.2 (65.3 to 83.1)79.2 (67.7 to 90.7)
SecondaryDuration of Response (DoR)

Duration of Response (DoR) is defined as the time between the date of first confirmed response to the date of the first documented tumor progression (per RECIST 1.1), or death due to any cause, whichever occurs first.

Time frame:
Up to 45 months
Reported as:
Median · month
Duration of Response (DoR)
monthArm 1Arm 2
Duration of Response (DoR)9 (7.6 to 10.5)7.6 (4.9 to 10.4)
Secondary6-months Progression-free Survival Rate

Probability of progression at 6 months.

Time frame:
6 months
Reported as:
Number · percentage of participants
6-months Progression-free Survival Rate
percentage of participantsArm 1Arm 2
6-months Progression-free Survival Rate47.5 (37.3 to 57.7)50.0 (35.9 to 64.1)
SecondaryOverall Survival in Patients ≥ 70 Years.

OS is defined as the time between the date of randomization and the date of death.

Time frame:
Up to 45 months
Reported as:
Median · months
Overall Survival in Patients ≥ 70 Years.
monthsArm 1Arm 2
Overall Survival in Patients ≥ 70 Years.13.03 (3.9 to 22.2)14.54 (7.99 to 21.01)
SecondaryProgression Free Survival in Patients ≥ 70 Years.

PFS is defined as the time from randomization to the date of first documented disease progression, as assessed by the investigator using RECIST 1.1 criteria, or death due to any cause, whichever occurs first.

Time frame:
Up to 45 months
Reported as:
Median · month
Progression Free Survival in Patients ≥ 70 Years.
monthArm 1Arm 2
Progression Free Survival in Patients ≥ 70 Years.6.48 (2.22 to 10.73)9.97 (3.59 to 16.34)
SecondaryOverall Response Rate in Patients ≥ 70 Years.

ORR is defined as the number of subjects with a best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized subjects for each treatment group.

Time frame:
Up to 2 years
Reported as:
Number · percentage of participants
Overall Response Rate in Patients ≥ 70 Years.
percentage of participantsArm 1Arm 2
Overall Response Rate in Patients ≥ 70 Years.40.553.8
SecondaryOverall Survival Based on PDL1 Expression (CPS).

OS is defined as the time between the date of randomization and the date of death.

Time frame:
Up to 45 months
Reported as:
Median · months
Overall Survival Based on PDL1 Expression (CPS).
monthsArm 1 - CPS <1Arm 1 - CPS >=1Arm 2 - CPS <1Arm 2 - CPS >=1
Overall Survival Based on PDL1 Expression (CPS).11.94 (8.55 to 15.33)12.24 (8.90 to 15.57)14.54 (7.51 to 21.57)11.18 (8.99 to 13.38)
SecondaryProgression Free Survival Based on PDL1 Expression (CPS).

PFS is defined as the time from randomization to the date of first documented disease progression, as assessed by the investigator using RECIST 1.1 criteria, or death due to any cause, whichever occurs first.

Time frame:
Up to 45 months
Reported as:
Median · months
Progression Free Survival Based on PDL1 Expression (CPS).
monthsArm 1 - CPS <1Arm 1 - CPS >=1Arm 2 - CPS <1Arm 2 - CPS >=1
Progression Free Survival Based on PDL1 Expression (CPS).7.6 (0.55 to 14.65)5.56 (4.16 to 6.95)8.72 (2.65 to 14.79)5.33 (2.94 to 7.71)
SecondaryOverall Response Rate Based on PDL1 Expression (CPS).

ORR is defined as the number of subjects with a best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized subjects for each treatment group.

Time frame:
Up to 2 years
Reported as:
Number · percentage of participants
Overall Response Rate Based on PDL1 Expression (CPS).
percentage of participantsArm 1 - CPS <1Arm 1 - CPS >=1Arm 2 - CPS <1Arm 2 - CPS >=1
Overall Response Rate Based on PDL1 Expression (CPS).45.035.627.340.5
SecondaryOverall Survival Based on Cisplatin Ineligibility.

OS is defined as the time between the date of randomization and the date of death.

Time frame:
Up to 45 months
Reported as:
Median · months
Overall Survival Based on Cisplatin Ineligibility.
monthsArm 1 - Group 1Arm 1 - Group 2Arm 1 - Group 3Arm 2 - Group 1Arm 2 - Group 2Arm 2 - Group 3
Overall Survival Based on Cisplatin Ineligibility.8.95 (2.08 to 15.82)14.14 (11.39 to 16.90)10.49 (6.55 to 14.44)7.5 (4.83 to 10.16)14.54 (8.85 to 20.23)12.14 (7.7 to 16.61)
SecondaryProgression Free Survival Based on Cisplatin Ineligibility.

PFS is defined as the time from randomization to the date of first documented disease progression, as assessed by the investigator using RECIST 1.1 criteria, or death due to any cause, whichever occurs first.

Time frame:
Up to 45 months
Reported as:
Median · months
Progression Free Survival Based on Cisplatin Ineligibility.
monthsArm 1 - Group 1Arm 1 - Group 2Arm 1 - Group 3Arm 2 - Group 1Arm 2 - Group 2Arm 2 - Group 3
Progression Free Survival Based on Cisplatin Ineligibility.4.84 (0.11 to 9.56)5.56 (3.02 to 8.1)10.23 (6.63 to 16.83)2.53 (1.78 to 3.24)7.53 (6.64 to 8.43)8.26 (6.8 to 9.71)
SecondaryOverall Response Rate Based on Cisplatin Ineligibility.

ORR is defined as the number of subjects with a best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized subjects for each treatment group.

Time frame:
Up to 2 years
Reported as:
Number · percentage of participants
Overall Response Rate Based on Cisplatin Ineligibility.
percentage of participantsArm 1 - Group 1Arm 1 - Group 2Arm 1 - Group 3Arm 2 - Group 1Arm 2 - Group 2Arm 2 - Group 3
Overall Response Rate Based on Cisplatin Ineligibility.32.039.640.015.451.925.0
SecondaryOverall Survival Based on Karnofsky.

OS is defined as the time between the date of randomization and the date of death.

Time frame:
Up to 45 months
Reported as:
Median · months
Overall Survival Based on Karnofsky.
monthsArm 1 - Karnofsky-PS 70%Arm 1 - Karnofsky-PS 80-100%Arm 2 - Karnofsky-PS 70%Arm 2 - Karnofsky-PS 80-100%
Overall Survival Based on Karnofsky.13.03 (10.04 to 16.01)11.32 (6.45 to 16.19)11.18 (6.48 to 15.89)12.14 (10.68 to 13.59)
SecondaryProgression Free Survival Based on Karnofsky.

PFS is defined as the time from randomization to the date of first documented disease progression, as assessed by the investigator using RECIST 1.1 criteria, or death due to any cause, whichever occurs first.

Time frame:
Up to 45 months
Reported as:
Median · months
Progression Free Survival Based on Karnofsky.
monthsArm 1 - Karnofsky-PS 70%Arm 1 - Karnofsky-PS 80-100%Arm 2 - Karnofsky-PS 70%Arm 2 - Karnofsky-PS 80-100%
Progression Free Survival Based on Karnofsky.6.48 (3.39 to 9.56)5.56 (4.2 to 6.92)4.84 (3.80 to 5.87)7.07 (3.38 to 10.76)
SecondaryOverall Response Rate Based on Karnofsky.

ORR is defined as the number of subjects with a best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized subjects for each treatment group.

Time frame:
Up to 2 years
Reported as:
Number · percentage of participants
Overall Response Rate Based on Karnofsky.
percentage of participantsArm 1 - Karnofsky-PS 70%Arm 1 - Karnofsky-PS 80-100%Arm 2 - Karnofsky-PS 70%Arm 2 - Karnofsky-PS 80-100%
Overall Response Rate Based on Karnofsky.41.635.143.734.4
SecondaryPercentage of Patients With AEs

Percentage of patients with AEs in relation with total number of treated patients

Time frame:
2 years
Reported as:
Number · percentage of participants
Percentage of Patients With AEs
percentage of participantsArm 1Arm 2
Percentage of Patients With AEs100100
SecondaryPercentage of Patients With Grade 3 and Grade 4 AEs

Percentage of patients with Grade 3 and Grade 4 AEs in relation with total number of treated patients

Time frame:
2 years
Reported as:
Number · percentage of participants
Percentage of Patients With Grade 3 and Grade 4 AEs
percentage of participantsArm 1Arm 2
Percentage of Patients With Grade 3 and Grade 4 AEs72.068.8
SecondaryPercentage of Patients With SAEs

Percentage of patients with SAEs in relation with total number of treated patients

Time frame:
Up to 45 months
Reported as:
Number · percentage of participants
Percentage of Patients With SAEs
percentage of participantsArm 1Arm 2
Percentage of Patients With SAEs57.054.2
SecondaryPercentage of Patients Who Discontinued Due to AEs

Percentage of patients who discontinued due to AEs in relation with total number of treated patients

Time frame:
Up to 2 years
Reported as:
Number · percentage of participants
Percentage of Patients Who Discontinued Due to AEs
percentage of participantsArm 1 - Combination PhaseArm 1 - Monotherapy PhaseArm 2 - Combination PhaseArm 2 - Monotherapy Phase
Percentage of Patients Who Discontinued Due to AEs14.010.210.46.1

Adverse events

Collected over Up to 45 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 179/93 (84.9%)53/93 (57%)93/93 (100%)
Arm 243/48 (89.6%)26/48 (54.2%)48/48 (100%)
Most frequent serious events
Showing 10 of 73
Most frequent serious events
EventArm 1Arm 2
Respiratory tract infectionInfections and infestations6/936/48
PneumoniaInfections and infestations9/932/48
DysphagiaGastrointestinal disorders7/931/48
Respiratory failureRespiratory, thoracic and mediastinal disorders6/931/48
VomitingGastrointestinal disorders0/932/48
Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/931/48
SepsisInfections and infestations3/931/48
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/931/48
Product dispensing errorInjury, poisoning and procedural complications2/930/48
Immune-mediated hepatitisHepatobiliary disorders2/930/48
Most frequent other events
Showing 10 of 62
Most frequent other events
EventArm 1Arm 2
AstheniaGeneral disorders57/9329/48
RashSkin and subcutaneous tissue disorders10/9325/48
AnaemiaBlood and lymphatic system disorders41/9319/48
Mucosal inflammationGeneral disorders15/9316/48
HypomagnesaemiaMetabolism and nutrition disorders6/9315/48
ConstipationGastrointestinal disorders23/9314/48
DiarrhoeaGastrointestinal disorders26/9314/48
Decreased appetiteMetabolism and nutrition disorders17/9314/48
AlopeciaSkin and subcutaneous tissue disorders26/936/48
NeurotoxicityNervous system disorders22/9310/48

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Arm 1Arm 2Total
<=18 years000
Between 18 and 65 years422769
>=65 years512172
Age, Continuous
Age, Continuous(years)Arm 1Arm 2Total
Mean66.8 (59 to 75)64 (57 to 70.5)65.9 (58 to 74)
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1Arm 2Total
Female201232
Male7336109
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm 1Arm 2Total
White/Caucasian9347140
Arab011
Smoking habits: Has the patient ever smoked?
Smoking habits: Has the patient ever smoked?(Participants)Arm 1Arm 2Total
Yes751186
No183755
Metastatic disease at diagnosis
Metastatic disease at diagnosis(Participants)Arm 1Arm 2Total
Yes8311
No8545130
Karnofsky performance status
Karnofsky performance status(Participants)Arm 1Arm 2Total
70%361652
80-100%573289
PD-L1 CPS
PD-L1 CPS(Participants)Arm 1Arm 2Total
<1201131
≥17337110

5 further baseline measures are reported on the registry.

08

Study locations

21 sites
  • Hospital Universitario Marqués de Valdecilla
    Santander, Cantabria 39008, Spain
  • Hospital Universitario Donostia- Donostia Unibertsitate Ospitalea
    San Sebastián, San Sebastían 20014, Spain
  • Centro Oncoloxico de Galicia
    A Coruña, 15009, Spain
  • Hospital Universitari Germans Trias i Pujol de Badalona
    Badalona, 08916, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Clínic de Barcelona
    Barcelona, 08036, Spain
  • Institut Català D´Oncologia- Hospital Duran i Reynals
    Barcelona, 08908, Spain
  • Hospital Universitari de Girona Dr. Josep
    Girona, 17007, Spain
  • Hospital Universitario Virgen de las Nieves
    Granada, 18014, Spain
  • Hospital Universitario Lucus Augusti
    Lugo, 27003, Spain
  • Hospital Clínico San Carlos
    Madrid, 28040, Spain
  • Hospital 12 de Octubre
    Madrid, Spain
  • Hospital Universitario Regional de Málaga
    Málaga, 29010, Spain
  • Complejo Hospitalario de Navarra
    Pamplona, 31008, Spain
  • Complejo Asistencial Universitario de Salamanca
    Salamanca, 37007, Spain
  • Hospital Universitario Virgen del Rocío
    Seville, 41013, Spain
  • Hospital Virgen de la Salud
    Toledo, 45004, Spain
  • Hospital Clínico Universitario de Valencia
    Valencia, 46010, Spain
  • Hospital Universitario y Politécnico la Fe
    Valencia, 46026, Spain
  • Hospital Clínico Universitario Lozano
    Zaragoza, 50009, Spain
  • Hospital Universitario Miguel Servet
    Zaragoza, 50009, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Sep 2023, 38 months.

Results were first posted in Jun 2025, 1 year 9 months after primary completion.

Of 299 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's 38 months is below that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2020
First posted
Feb 24, 2020
StartActual
Jun 3, 2020
Primary completionActual
Sep 1, 2023
CompletionActual
Mar 21, 2024
Results first posted
Jun 26, 2025
Last update
Jun 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04282109
Lead sponsor
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Collaborators
Bristol-Myers Squibb, Apices Soluciones S.L.
Responsible party
Sponsor
First posted
Feb 24, 2020
Start date
Jun 3, 2020
Primary completion
Sep 1, 2023
Completion
Mar 21, 2024
Results posted
Jun 26, 2025
Last update
Jun 26, 2025

Study contacts

Ricard Mesia, MD
principal investigator · Hospital Universitari Germans Trias i Pujol de Badalona
Lara Iglesias, MD
principal investigator · Hospital Universitario 12 de Octubre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Paclitaxel

Start the discussion